News & Updates
Filter by Specialty:
Xanomeline–trospium beneficial in treatment of schizophrenia
Treatment with the combination of xanomeline plus trospium leads to favourable reduction in positive and negative symptoms in patients with schizophrenia, while being well tolerated, according to data from the phase III EMERGENT-2 trial.
Xanomeline–trospium beneficial in treatment of schizophrenia
16 Jan 2024
Tricyclic antidepressant for IBS worth a try
The tricyclic antidepressant amitriptyline, when used at low dose in the second-line treatment setting and titrated according to symptom response and side-effects, is safe and provides relief from symptoms of irritable bowel syndrome (IBS), as shown in the phase III ATLANTIS* trial.
Tricyclic antidepressant for IBS worth a try
15 Jan 2024
Voice-based AI makes insulin management a breeze for T2D patients
A voice-based conversational artificial intelligence application helps type 2 diabetes (T2D) patients navigate basal insulin titration at home and, in turn, achieve rapid glycaemic control, as reported in a study.
Voice-based AI makes insulin management a breeze for T2D patients
13 Jan 2024
Maintenance olaparib rechallenge improves PFS in ovarian cancer patients
Restarting treatment with maintenance olaparib in ovarian cancer patients who had received one prior poly(ADP-ribose) polymerase (PARP) inhibitor and at least two lines of platinum-based chemotherapy results in a modest but significant improvement in progression-free survival (PFS) compared with placebo, results of a phase III study have shown.
